Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative (NCT04842617) | Jiangsu HengRui Medicine Co., Ltd. | 2021-04-30 |
Track Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.